MITOCHONDRIAL-DERIVED PEPTIDE MOTS3 REGULATES METABOLISM AND CELL SURVIVAL
MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
1 . An isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1.
2 . The polypeptide of claim 1 , comprising 80% sequence identity to SEQ ID NO:1.
3 . The polypeptide of claim 1 , comprising 90% sequence identity to SEQ ID NO:1.
4 . The polypeptide of claim 1 , comprising the sequence of SEQ ID NO:1.
5 . An isolated antibody that specifically binds to the polypeptide comprising 70% sequence identity to SEQ ID NO: 1.
6 . The antibody of claim 5 , wherein the antibody is a monoclonal antibody.
7 . A pharmaceutical composition comprising an isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1.
8 . The composition of claim 7 , wherein the polypeptide comprises 80% or 90% sequence identity to SEQ ID NO:1.
9 . The composition of claim 7 , wherein the polypeptide comprises the sequence of SEQ ID NO:1.
10 . A method of treating diabetes, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1.
11 . The method of claim 10 , wherein the polypeptide comprises 80% or 90% sequence identity to SEQ ID NO:1.
12 . The method of claim 10 , wherein the polypeptide comprises the sequence of SEQ ID NO:1.
13 . The method of claim 10 , wherein the diabetes is type I diabetes.
14 . The method of claim 10 , wherein the diabetes is type II diabetes.
15 . The method of claim 10 , wherein the subject is a human.
16 . A method of treating obesity and/or fatty liver, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1.
17 . The method of claim 16 , wherein the polypeptide comprises 80% or 90% sequence identity to SEQ ID NO:1.
18 . The method of claim 16 , wherein the polypeptide comprises the sequence of SEQ ID NO:1.
19 . The method of claim 16 , wherein the subject is a human.
20 . A method of treating cancer, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated polypeptide comprising 70% sequence identity to SEQ ID NO:1.
21 . The method of claim 20 , wherein the polypeptide comprises 80% or 90% sequence identity to SEQ ID NO:1.
22 . The method of claim 20 , wherein the polypeptide comprises the sequence of SEQ ID NO:1.
23 . The method of claim 20 , wherein the subject is a human.
24 . The method of claim 20 , wherein the cancer is a cancer selected from a group consisting of breast cancer, brain cancer, colon cancer, melanoma, leukemia (e.g., AML), lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, lung cancer, and gastric cancer.